Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Common Equity: 2019-2024

Historic Common Equity for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $527.0 million.

  • Nurix Therapeutics' Common Equity fell 1.22% to $372.3 million in Q3 2025 from the same period last year, while for Aug 2025 it was $372.3 million, marking a year-over-year decrease of 1.22%. This contributed to the annual value of $527.0 million for FY2024, which is 162.85% up from last year.
  • According to the latest figures from FY2024, Nurix Therapeutics' Common Equity is $527.0 million, which was up 162.85% from $200.5 million recorded in FY2023.
  • Nurix Therapeutics' Common Equity's 5-year high stood at $527.0 million during FY2024, with a 5-year trough of $200.5 million in FY2023.
  • Its 3-year average for Common Equity is $343.7 million, with a median of $303.7 million in 2022.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 602.94% in 2020, then tumbled by 33.98% in 2023.
  • Nurix Therapeutics' Common Equity (Yearly) stood at $290.3 million in 2020, then climbed by 17.93% to $342.3 million in 2021, then decreased by 11.28% to $303.7 million in 2022, then crashed by 33.98% to $200.5 million in 2023, then spiked by 162.85% to $527.0 million in 2024.